While numerous blood pressure monitors exist on the market, few smartwatches offer clinically validated tracking. Huawei’s newly unveiled Watch D2 challenges this gap as the first wrist-worn device with ambulatory blood pressure monitoring, certified by both China’s National Medical Products Association and the EU’s Medical Device Regulation.
Huawei emphasizes the Watch D2’s portability, noting it is one-fifth the width and 1/25th the volume of traditional electronic monitors. The device continuously measures blood pressure over 24-hour periods, using its TruSense System to enhance accuracy and detect long-term patterns—valuable for hypertension and cardiovascular patients. Currently, the smartwatch is unavailable in the U.S.
Competitors Lag Behind in Standalone Functionality
Other smartwatches, like Samsung’s Galaxy Watch 7, require calibration with a cuff-based monitor and lack FDA approval for diagnostic use. Similarly, Apple Watch aggregates blood pressure data but cannot take independent measurements. Industry analysts speculate Apple may introduce BP monitoring in its Ultra 3 model, though past delays cast uncertainty.
Market Growth Driven by Rising Health Concerns
Fortune Business Insights projects the blood pressure monitor market to grow at a 9.2% annual rate through 2032, fueled by increasing cases of hypertension and cardiac arrhythmia. Wider adoption of wearable BP tech could help detect undiagnosed high blood pressure, a silent contributor to severe health risks.
For now, Huawei’s Watch D2 stands out as a rare, medically endorsed option—if accessibility expands beyond current markets.
